Tirabrutinib

Drug Profile

Tirabrutinib

Alternative Names: GS-4059; ONO-4059

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Gilead Sciences; Ono Pharmaceutical
  • Class Antineoplastics; Purines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Sjogren's syndrome
  • Phase I B cell lymphoma; Rheumatoid arthritis
  • Preclinical Systemic lupus erythematosus

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase Ib trial in B-cell lymphoma (Combination therapy, Second-line therapy or greater) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 May 2017 Phase-II clinical trials in Sjogren's syndrome (In the elderly, In adults) in USA, United Kingdom (PO) (NCT03100942)
  • 21 Apr 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top